1480 related articles for article (PubMed ID: 15284307)
1. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.
Block GA; Klassen PS; Lazarus JM; Ofsthun N; Lowrie EG; Chertow GM
J Am Soc Nephrol; 2004 Aug; 15(8):2208-18. PubMed ID: 15284307
[TBL] [Abstract][Full Text] [Related]
2. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
[TBL] [Abstract][Full Text] [Related]
3. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
[TBL] [Abstract][Full Text] [Related]
4. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study.
Naves-Díaz M; Passlick-Deetjen J; Guinsburg A; Marelli C; Fernández-Martín JL; Rodríguez-Puyol D; Cannata-Andía JB
Nephrol Dial Transplant; 2011 Jun; 26(6):1938-47. PubMed ID: 20513773
[TBL] [Abstract][Full Text] [Related]
5. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis.
Danese MD; Kim J; Doan QV; Dylan M; Griffiths R; Chertow GM
Am J Kidney Dis; 2006 Jan; 47(1):149-56. PubMed ID: 16377396
[TBL] [Abstract][Full Text] [Related]
6. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study.
Slinin Y; Foley RN; Collins AJ
J Am Soc Nephrol; 2005 Jun; 16(6):1788-93. PubMed ID: 15814832
[TBL] [Abstract][Full Text] [Related]
7. Mineral metabolism and mortality in dialysis patients: a reassessment of the K/DOQI guideline.
Noordzij M; Korevaar JC; Dekker FW; Boeschoten EW; Bos WJ; Krediet RT; Bossuyt PM; Geskus RB;
Blood Purif; 2008; 26(3):231-7. PubMed ID: 18305386
[TBL] [Abstract][Full Text] [Related]
8. Associates of mortality and hospitalization in hemodialysis: potentially actionable laboratory variables and vascular access.
Lacson E; Wang W; Hakim RM; Teng M; Lazarus JM
Am J Kidney Dis; 2009 Jan; 53(1):79-90. PubMed ID: 18930570
[TBL] [Abstract][Full Text] [Related]
9. Factors modulating cytosolic calcium. Role in lipid metabolism and cardiovascular morbidity and mortality in peritoneal dialysis patients.
Gadallah MF; el-Shahawy M; Andrews G; Ibrahim M; Ramdeen G; Hanna D; Gorospe W; Morkos A; Abbassian M; Moles K
Adv Perit Dial; 2001; 17():29-36. PubMed ID: 11510292
[TBL] [Abstract][Full Text] [Related]
10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
11. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients.
Noordzij M; Korevaar JC; Bos WJ; Boeschoten EW; Dekker FW; Bossuyt PM; Krediet RT
Nephrol Dial Transplant; 2006 Sep; 21(9):2513-20. PubMed ID: 16799173
[TBL] [Abstract][Full Text] [Related]
12. Mineral metabolism disturbances in patients with chronic kidney disease.
Kestenbaum B; Belozeroff V
Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
[TBL] [Abstract][Full Text] [Related]
13. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
Nasri H; Baradaran A; Naderi AS
Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
[TBL] [Abstract][Full Text] [Related]
14. Disordered mineral metabolism is not a risk factor for loss of residual renal function in dialysis patients.
Noordzij M; Voormolen NM; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT; Korevaar JC;
Nephrol Dial Transplant; 2009 May; 24(5):1580-7. PubMed ID: 19155531
[TBL] [Abstract][Full Text] [Related]
15. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
Nasri H; Baradaran A
J Ayub Med Coll Abbottabad; 2004; 16(2):3-8. PubMed ID: 15455608
[TBL] [Abstract][Full Text] [Related]
16. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD.
Menon V; Greene T; Pereira AA; Wang X; Beck GJ; Kusek JW; Collins AJ; Levey AS; Sarnak MJ
Am J Kidney Dis; 2005 Sep; 46(3):455-63. PubMed ID: 16129207
[TBL] [Abstract][Full Text] [Related]
17. Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism.
Costa-Hong V; Jorgetti V; Gowdak LH; Moyses RM; Krieger EM; De Lima JJ
Surgery; 2007 Nov; 142(5):699-703. PubMed ID: 17981190
[TBL] [Abstract][Full Text] [Related]
18. The need for better control of secondary hyperparathyroidism.
Locatelli F
Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V15-19. PubMed ID: 15284355
[TBL] [Abstract][Full Text] [Related]
19. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
Bhuriya R; Li S; Chen SC; McCullough PA; Bakris GL
Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
[TBL] [Abstract][Full Text] [Related]
20. Influence of sevelamer on mineral metabolism and hyperparathyroidism in Japanese hemodialysis patients.
Inoue T; Nagatoya K; Kagitani M; Shibahara N; Ueda H; Katsuoka Y; Ohashi S; Kitagawa Y; Nishimoto K; Yasuda H;
Ther Apher Dial; 2007 Jun; 11(3):210-4. PubMed ID: 17498003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
